NOVO.B.DK

376.15

+0.87%↑

COLO.B.DK

568.2

-0.39%↓

HLUNB.DK

45.4

+1.29%↑

ZEAL.DK

511.4

+1.03%↑

AMBUB.DK

106.4

+2.7%↑

NOVO.B.DK

376.15

+0.87%↑

COLO.B.DK

568.2

-0.39%↓

HLUNB.DK

45.4

+1.29%↑

ZEAL.DK

511.4

+1.03%↑

AMBUB.DK

106.4

+2.7%↑

NOVO.B.DK

376.15

+0.87%↑

COLO.B.DK

568.2

-0.39%↓

HLUNB.DK

45.4

+1.29%↑

ZEAL.DK

511.4

+1.03%↑

AMBUB.DK

106.4

+2.7%↑

NOVO.B.DK

376.15

+0.87%↑

COLO.B.DK

568.2

-0.39%↓

HLUNB.DK

45.4

+1.29%↑

ZEAL.DK

511.4

+1.03%↑

AMBUB.DK

106.4

+2.7%↑

NOVO.B.DK

376.15

+0.87%↑

COLO.B.DK

568.2

-0.39%↓

HLUNB.DK

45.4

+1.29%↑

ZEAL.DK

511.4

+1.03%↑

AMBUB.DK

106.4

+2.7%↑

Search

Genmab A-S

Atvērts

2,090 2.6

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2046

Max

2091

Galvenie mērījumi

By Trading Economics

Ienākumi

228M

423M

Pārdošana

210M

925M

P/E

Sektora vidējais

14.812

35.739

EPS

34.77

Peļņas marža

45.73

Darbinieki

2,639

EBITDA

448M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

-1.49% downside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

26B

113B

Iepriekšējā atvēršanas cena

2087.4

Iepriekšējā slēgšanas cena

2090

Genmab A-S Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. aug. 15:10 UTC

Galvenie tirgus virzītāji

Genmab Shares Rise After Positive Results for Epcoritamab Trial

2025. g. 10. marts 15:16 UTC

Galvenie tirgus virzītāji

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

2024. g. 10. dec. 07:05 UTC

Tirgus saruna

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Salīdzinājums

Cenas izmaiņa

Genmab A-S Prognoze

Cenas mērķis

By TipRanks

-1.49% uz leju

Prognoze 12 mēnešiem

Vidējais 2,493.35 DKK  -1.49%

Augstākais 3,320 DKK

Zemākais 308.417 DKK

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Genmab A-S — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

7 ratings

3

Pirkt

2

Turēt

2

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat